Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS. Montalban X, et al. Among authors: harlow de. Mult Scler. 2024 Apr;30(4-5):558-570. doi: 10.1177/13524585241234783. Epub 2024 Mar 4. Mult Scler. 2024. PMID: 38436271 Free PMC article. Clinical Trial.
The effect of disease modifying therapies on fatigue in multiple sclerosis.
Cruz Rivera S, Aiyegbusi OL, Piani Meier D, Dunne A, Harlow DE, Henke C, Kamudoni P, Calvert MJ. Cruz Rivera S, et al. Among authors: harlow de. Mult Scler Relat Disord. 2023 Nov;79:105065. doi: 10.1016/j.msard.2023.105065. Epub 2023 Oct 10. Mult Scler Relat Disord. 2023. PMID: 37839365 Free article. Review.
Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy.
Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Manca L, Harlow DE, Phillips AL. Nicholas JA, et al. Among authors: harlow de. Mult Scler J Exp Transl Clin. 2022 Jun 30;8(2):20552173221101150. doi: 10.1177/20552173221101150. eCollection 2022 Apr-Jun. Mult Scler J Exp Transl Clin. 2022. PMID: 35795102 Free PMC article.
Remyelination Therapy in Multiple Sclerosis.
Harlow DE, Honce JM, Miravalle AA. Harlow DE, et al. Front Neurol. 2015 Dec 10;6:257. doi: 10.3389/fneur.2015.00257. eCollection 2015. Front Neurol. 2015. PMID: 26696956 Free PMC article. Review.
14 results